HRTX Q2 2023 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$32M+15.0% YoY

Gross Profit

$12M36.5% margin

Operating Income

-$42M-133.5% margin

Net Income

-$42M-132.4% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$201M

Total Liabilities

$241M

Stockholders' Equity

-$39M

Cash & Equivalents

$13M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$32M	$28M	+15.0%
Gross Profit	$12M	$11M	+1.3%
Operating Income	-$42M	-$49M	+14.3%
Net Income	-$42M	-$56M	+25.4%

Revenue Segments

C I N V A N T I

$24M78%

Z Y N R E L E F

$4M13%

S U S T O L

$3M9%